Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.24) by 41.08 percent. This is a 277.78 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $24.289 million which missed the analyst consensus estimate of $24.481 million by 0.79 percent. This is a 83.66K percent increase over sales of $29.000 thousand the same period last year.